Trial Site Detail
Drug: |
Entrectinib |
|||
|---|---|---|---|---|
Trial: |
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK1/2/3, ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2) |
|||
| Conditions: | Gastrointestinal Stromal Tumor | |||
Trial Status: |
Active, not recruiting |
|||
Henry Ford Health System |
Principal Investigator: |
|
|---|---|
Contact: |
Contact: Ding Wang, MD |
Activation Status of this Site: |
Closed |
Notes about this Site: |
|
Henry Ford Health System Website: |
Navigating the Map
Use the plus (+) and minus (-) controls to zoom in/out.
Click and drag the map or use the arrows to move (pan) the map.
Tip: Click the marker before zooming and the map will stay centered on the marker as you zoom.